Management of young women with early breast cancer

Francesca Poggio, Matteo Lambertini, Claudia Bighin, Benedetta Conte, Eva Blondeaux, Alessia D'Alonzo, Chiara Dellepiane, Francesco Boccardo, Lucia Del Mastro, Francesca Poggio, Matteo Lambertini, Claudia Bighin, Benedetta Conte, Eva Blondeaux, Alessia D'Alonzo, Chiara Dellepiane, Francesco Boccardo, Lucia Del Mastro

Abstract

Breast cancer is still the most frequent cancer diagnosed in women aged ≤40 years and the primary cause of death in this age group. The management of these patients needs a dedicated approach involving a multidisciplinary team that takes into account their treatment and survivorship issues. The present review aims to provide a perspective on the many challenges associated with treatment of young women with early breast cancer. We will focus on the standard (neo)adjuvant treatment, highlighting the paucity of age-specific results about the available genomic signatures, the groundbreaking landscape of adjuvant endocrine therapy and the relevant issue of the fertility preservation.

Keywords: adjuvant treatments; breast cancer; fertility; premenopausal; young women.

Conflict of interest statement

Competing interests: LDM received honoraria from Takeda and personal fees from Ipsen and Takeda outside the submitted work. ML served as a consultant for Teva and received honoraria from Theramex outside the submitted work.

References

    1. Brinton LA, Sherman ME, Carreon JD, et al. . Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 2008;100:1643–8. 10.1093/jnci/djn344
    1. Lee SK, Kim SW, Yu JH, et al. Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer? Breast Cancer Res Treat. 2018 doi: 10.1007/s10549-018-4947-z.
    1. Lambertini M, Santoro L, Del Mastro L, et al. . Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies. Cancer Treat Rev 2016;49:65–76. 10.1016/j.ctrv.2016.07.006
    1. Fidler MM, Gupta S, Soerjomataram I, et al. . Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol 2017;18:1579–89. 10.1016/S1470-2045(17)30677-0
    1. Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res 2014;16:427 10.1186/s13058-014-0427-5
    1. Partridge AH, Hughes ME, Warner ET, et al. . Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol 2016;34:3308–14. 10.1200/JCO.2015.65.8013
    1. Paluch-Shimon S, Pagani O, Partridge AH, et al. . ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast 2017;35:203–17. 10.1016/j.breast.2017.07.017
    1. Del Mastro L, De Placido S, Bruzzi P, et al. . Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. The Lancet 2015;385:1863–72. 10.1016/S0140-6736(14)62048-1
    1. Lambertini M, Ceppi M, Cognetti F, et al. . Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies. Eur J Cancer 2017;71:34–42. 10.1016/j.ejca.2016.10.030
    1. Gray R, Bradley R, Braybrooke J, et al. . Abstract GS1-01: Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials. Cancer Res 2018;78(4 Suppl):GS1-01 10.1158/1538-7445.SABCS17-GS1-01
    1. Poggio F, Bruzzone M, Ceppi M, et al. . Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol 2018;29:1497–508. 10.1093/annonc/mdy127
    1. Sparano JA, Gray RJ, Makower DF, et al. . Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111–21. 10.1056/NEJMoa1804710
    1. Lambertini M, Viglietti G, de Azambuja E. Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer. Curr Opin Oncol 2018:1 10.1097/CCO.0000000000000491
    1. Francis PA, Pagani O, Fleming GF, et al. . Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379:122–37. 10.1056/NEJMoa1803164
    1. Hershman DL, Shao T, Kushi LH, et al. . Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126:529–37. 10.1007/s10549-010-1132-4
    1. Lambertini M, Viglietti G, de Azambuja E. Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? ESMO Open 2018;3:e000350 10.1136/esmoopen-2018-000350
    1. Bellet M, Gray KP, Francis PA, et al. . Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): the SOFT-EST Substudy. J Clin Oncol 2016;34:1584–93. 10.1200/JCO.2015.61.2259
    1. Regan MM, Walley BA, Francis PA, et al. . Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 2017;28:2225–32. 10.1093/annonc/mdx285
    1. Lambertini M, Moore HCF, Leonard RCF, et al. . Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol 2018;36:1981–90. 10.1200/JCO.2018.78.0858
    1. Ruddy KJ, Gelber SI, Tamimi RM, et al. . Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014;32:1151–6. 10.1200/JCO.2013.52.8877
    1. Lambertini M, Fontana V, Massarotti C, et al. . Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. Breast 2018;41:51–6. 10.1016/j.breast.2018.06.012
    1. Peccatori FA, Azim HA, Orecchia R, et al. . Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi160–vi170. 10.1093/annonc/mdt199
    1. Oktay K, Harvey BE, Partridge AH, et al. . Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018;36:1994–2001. 10.1200/JCO.2018.78.1914
    1. Lambertini M, Kroman N, Ameye L, et al. . Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst 2018;110:426–9. 10.1093/jnci/djx206
    1. Freedman RA, Partridge AH. Emerging data and current challenges for young, old, obese, or male patients with breast cancer. Clin Cancer Res 2017;23:2647–54. 10.1158/1078-0432.CCR-16-2552

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する